Tilray Brands, Inc. (TLRY) Analysis

With global ambitions expanding and potential cannabis reclassification, should investors brace for upside? Or prepare for another volatile season?

Do I get some free Doobie/Buddha's delight? Either I smoke my next joint in my vacation home or on the street after losing my current home.

It started with $1,000,000 of my "friend's" money. That’s right. A whole million, corporate-sanctioned tendie tokens. I was told to “diversify” and “manage risk” and “absolutely not yeet it all into stonks named after weed.” LOL. At first, I crushed. Turned that stash into $1.7M in under a month. I thought I was the next Warren Buffett — if Buffett only invested while crossfaded. My spreadsheets had macros. My vocabulary had “gross margin compression” and “dilutive issuance” in it. My Tinder bi...

Alex Bruesewitz, Trump advisor, recently commented on X that cannabis rescheduling is an 80-20 issue among all voters and a 70-30 issue among Republican voters. He also made it clear: > If President Trump moves forward with rescheduling, Alex believes it will be *well received* politically. My take: While rescheduling wouldn’t fully legalize cannabis, the market often reacts *immediately* to political momentum. Even if the fundamental revenue boost for companies like $TLRY takes longer, the s...

Ticker Symbol: TLRY Tilray Brands is a pharmaceutical, cannabis and consumer packaged goods company, headquartered in New York City. They also have operations in Canada, Australia, New Zealand, and Latin America, with growing facilities in Germany and Portugal. The target price in the next 12 months ranges from $1.00-$3.00, while currently sitting at $0.69¢. Other sources are suggesting a target price of $1.18-$1.38. They are diversifying beyond cannabis, including expansions into craft beer...

Not sure how this isn’t getting more attention, but $TLRY is up another **3% after hours** today and has been steadily climbing the past couple of sessions. The volume has seriously picked up, and yet it's crickets over in WSB — not even a whisper from the usual retail crowd. We’ve seen some cannabis names quietly start to gain momentum, and TLRY is looking like it wants to break out. Whether it’s speculation on potential federal reform, earnings anticipation, or just a good ol’ momentum play, ...

Back in 2024, the move was mostly speculative. few real deals, no major international expansion, and a very uncertain political backdrop. Today, the cards are completely different: Real international expansion * Just yesterday, a deal was announced with Molteni in Italy. * New distribution channels and approvals are opening up the European market. Bigger and more diversified portfolio * More products in both medical and recreational cannabis. * Potential to boost revenue across multiple seg...

Tilray Brands is a pharmaceutical, cannabis and consumer packaged goods company, headquartered in New York City. They also have operations in Canada, Australia, New Zealand, and Latin America, with growing facilities in Germany and Portugal. The target price in the next 12 months ranges from $1.00-$3.00, while currently sitting at $0.69¢. Other sources are suggesting a target price of $1.18-$1.38. They are diversifying beyond cannabis, including expansions into craft beer, spirits, and wellne...

Today, Alan Brochstein, CFA, downgraded Tilray Brands ($TLRY) from *Buy* to *Neutral*, arguing that the company won’t directly benefit from the cannabis rescheduling speculation that recently fueled its rally. In my opinion, that analysis misses some important points: While it’s true that Tilray doesn’t currently get 100% of its revenue from the U.S., the company already has the infrastructure, licenses, and capital to quickly scale into the U.S. market if rescheduling happens. Even if sales i...

That’s going to be the headline one morning or late night!! Don’t miss your chance to be in the ship to the moon! 🚀🤪 Let’s go ROCKETARDS!!!